X100BEST Joint Powder - Website Content

Veterinary Educational Content | Dr. Aaron Buck, DVM

This content is transcribed from video and audio materials featuring Dr. Aaron Buck, DVM, and edited for clarity and educational purposes.

Joint Health in Dogs: A Structural System Approach Beyond Glucosamine

By Dr. Aaron Buck, DVM
University of Illinois College of Veterinary Medicine, Class of 2014

 

 

The Limitations of Single-Ingredient Thinking

In clinical practice, I field questions about joint health daily—from Great Dane puppies experiencing rapid growth to senior Labrador Retrievers showing stiffness on morning walks. A common misconception I encounter is that glucosamine alone constitutes adequate joint support.

The reality is more nuanced. A synovial joint functions as an integrated structural system with three distinct but interdependent components:

Evidence-Based Ingredients for Structural Support

1. Bioactive Collagen Peptides (BCP®)

Collagen type II constitutes 60% of cartilage dry weight. Bioactive collagen peptides—specifically FORTIGEL® (cartilage support), FORTIBONE® (bone matrix integrity), and TENDOFORTE® (connective tissue resilience)—have demonstrated in vitro chondroprotective effects and improved joint mobility markers in randomized human trials.

References: McAlindon et al., "Change in knee osteoarthritis cartilage..." Arthritis & Rheumatology; Clark et al., "24-Week study on collagen peptides..." Current Medical Research and Opinion.

2. Glycosaminoglycan Precursors

Glucosamine Hydrochloride: Provides substrate for proteoglycan synthesis
Chondroitin Sulfate: Maintains cartilage matrix hydration and compressive resistance

Meta-analyses show modest efficacy for osteoarthritis symptom modification when combined, with effect sizes varying by product quality and dosing consistency.

References: Towheed et al., Cochrane Database Syst Rev; Hochberg et al., Arthritis & Rheumatism.

3. Perna canaliculus (Green-Lipped Mussel)

Rich in omega-3 fatty acids (EPA/DHA) and glycosaminoglycans. New Zealand-sourced extracts have shown anti-inflammatory effects in canine osteoarthritis models at 20-50 mg/kg dosing ranges.

References: Bierer & Bui, Journal of Nutrition; Hielm-Björkman et al., Veterinary Journal.

4. Boswellia serrata Extract

A 5-lipoxygenase inhibitor providing comfort support through leukotriene pathway modulation. Veterinary studies indicate comparable efficacy to NSAIDs for mild-to-moderate joint discomfort, with favorable gastric tolerability profiles for long-term administration.

References: Reichling et al., Journal of Ethnopharmacology; Gupta et al., Phytomedicine.

Clinical Selection Criteria for Practitioners

1. 1. Structural comprehensiveness: Does the formula address cartilage, bone, and connective tissue simultaneously?

2. 2. Third-party verification: Are active ingredients tested by independent laboratories (NSF, USP, or ISO 17025-accredited facilities) to confirm label claim compliance?

3. 3. Dosing transparency: Are specific ingredient amounts disclosed, or hidden behind proprietary blends?

4. 4. Long-term safety profile: Is the comfort-support mechanism suitable for chronic administration without hepatic/renal stress?

Clinical Application

In my practice, I have observed improved mobility outcomes in canine patients receiving structurally comprehensive joint support, particularly in:

· Giant-breed puppies (6-18 months) during rapid growth phases

· Working and sporting dogs under repetitive joint load

· Geriatric patients (>8 years) with age-related cartilage degradation

· I also administer this category of supplementation to my own dogs as a preventive measure during high-activity training periods.

Disclosure

Dr. Buck serves as a paid veterinary consultant to X100BEST and participates in the brand's Veterinary Advisory Board. This article reflects his independent clinical assessment based on published ingredient science. No commission or royalty is received from product sales.

For specific dosing recommendations and contraindications, consult your attending veterinarian. This content is educational and does not replace professional medical diagnosis.

PART III: BCP® Global Patent Information

GELITA AG - Global Leader in Bioactive Collagen Peptides

· Founded: 1875 (Eberbach, Germany)

· Global Presence: 21 production sites + 4 offices across North America, South America, Europe, South Africa, Asia, Australia and New Zealand

· Specialization: Pioneer in Bioactive Collagen Peptides (BCP®) development

· Key Innovation: First company to develop bioactive collagen peptides with targeted physiological benefits (since 1990s)

· Certifications: ISO 9001, ISO 14001, ISO 50001, FSSC 22000

· FDA Status: GRAS (Generally Recognized as Safe) - Docket Number 77N-0232

· Regulatory: Compliant with Reg. (EC) No 853/2004

· Religious Certifications: Kosher & Halal available

 

  BCP® Product Portfolio & Target Cells

 

Key Patents Assigned to GELITA AG

US Patent Family (Confirmed)

· US-9072724-B2: Collagen peptide composition for joint health

· US-8778422-B2: Bioactive collagen peptide for connective tissue

· US-5948766-A: Collagen hydrolysate production method

· US-2019151399-A1: Nutritional collagen peptide formulations

· US-12419936-B2: Collagen peptide-based medicament compositions (2024)

· US-12528857: Nutritionally-optimized collagen peptide (Granted Jan 2026)

· US-12419321: Casting compound for gelatin products (Granted Sep 2025)

· US-12138297: Collagen hydrolysate for skin/intestinal disorders (Granted Nov 2024)

European & International Patents

· WO-2018187530-A1: International PCT application for collagen peptides

· EU Patent Portfolio: Comprehensive coverage across EU member states

· EP Applications: Multiple filings for BCP® production processes

Key Inventors

· Stephan Hausmanns

· Hans-Ulrich Frech

· Steffen Oesser

· Martin Hahn

· Suzane Leser

Clinical Study References

· Zdzieblik et al. (2021): FORTIGEL® reduces knee joint discomfort in young active adults - Published in Nutrients (MDPI)

· McAlindon et al.: Knee osteoarthritis cartilage study - Arthritis & Rheumatology

· Clark et al.: 24-week collagen peptide study - Current Medical Research and Opinion

· Note: Study effects are valid ONLY for specific BCP® products used in trials, not generic collagen

 

IMPORTANT NOTES FOR X100BEST PRODUCT CLAIMS

· BCP®, FORTIGEL®, FORTIBONE®, TENDOFORTE®, VERISOL®, BODYBALANCE®, PeptENDURE®, and PETAGILE® are registered trademarks of GELITA AG.

· Clinical study results cited are specific to GELITA's BCP® products and CANNOT be applied to generic collagen peptides from other manufacturers.

· GELITA maintains the industry's most extensive library of peer-reviewed clinical trials for collagen peptides.

· For product formulation using BCP® ingredients, contact GELITA directly for technical specifications and dosing recommendations.

· GELITA Headquarters: Uferstraße 7, 69412 Eberbach, Germany

· Contact: Oliver Wolf, Head of B2B Marketing (Global) - oliver.wolf@gelita.com